Soligenix Gestion

Gestion contrôle des critères 3/4

Le PDG Soligenix's est Christopher Schaber, nommé en Aug2006, a un mandat de 18.08 ans. La rémunération annuelle totale est $ 700.49K, composée du salaire de 74.2% et des bonus 25.8%, y compris les actions et options de la société. détient directement 0.017% des actions de la société, d'une valeur de $ 1.33K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 10.2 ans et 15.2 ans.

Informations clés

Christopher Schaber

Directeur général

US$700.5k

Rémunération totale

Pourcentage du salaire du PDG	74.2%
Durée du mandat du directeur général	18.2yrs
Propriété du PDG	0.02%
Durée moyenne d'occupation des postes de direction	10.3yrs
Durée moyenne du mandat des membres du conseil d'administration	15.3yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Christopher Schaber a-t-elle évolué par rapport aux bénéfices de Soligenix?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$7m
Mar 31 2024	n/a	n/a	-US$7m
Dec 31 2023	US$700k	US$519k	-US$6m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$711k	US$499k	-US$14m
Sep 30 2022	n/a	n/a	-US$15m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$687k	US$485k	-US$13m
Sep 30 2021	n/a	n/a	-US$13m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$944k	US$475k	-US$18m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$16m
Mar 31 2020	n/a	n/a	-US$15m
Dec 31 2019	US$688k	US$466k	-US$9m
Sep 30 2019	n/a	n/a	-US$10m
Jun 30 2019	n/a	n/a	-US$9m
Mar 31 2019	n/a	n/a	-US$8m
Dec 31 2018	US$619k	US$453k	-US$9m
Sep 30 2018	n/a	n/a	-US$8m
Jun 30 2018	n/a	n/a	-US$7m
Mar 31 2018	n/a	n/a	-US$8m
Dec 31 2017	US$674k	US$444k	-US$7m

Rémunération vs marché: La rémunération totale de Christopher ($USD 700.49K ) est supérieure à la moyenne des entreprises de taille similaire sur le marché UK ($USD 369.30K ).

Rémunération et revenus: La rémunération de Christopher a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Christopher Schaber (58 yo)

18.2yrs

Titularisation

US$700,485

Compensation

Dr. Christopher J. Schaber, Ph D., has been the President and Chief Executive Officer at Soligenix, Inc. since August 30, 2006. Dr. Schaber has broad experience in the pharmaceutical and biotechnology indu...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Christopher Schaber	Chairman of the Board of Directors	18.2yrs	US$700.49k	0.017% $ 1.5k
Jonathan Guarino	Senior VP	5.1yrs	US$354.69k	0.0020% $ 178.7
Oreola Donini	Senior VP & Chief Scientific Officer	9.8yrs	US$387.59k	0% $ 0
Richard Straube	Senior VP & Chief Medical Officer	10.8yrs	US$249.94k	0.0015% $ 131.8

10.3yrs

Durée moyenne de l'emploi

55yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 0A6I est chevronnée et expérimentée (ancienneté moyenne 10.1 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Christopher Schaber	Chairman of the Board of Directors	18.2yrs	US$700.49k	0.017% $ 1.5k
Jerome Zeldis	Independent Director	13.3yrs	US$72.50k	0.0042% $ 372.5
Gregory Lapointe	Independent Director	15.6yrs	US$77.50k	0.0014% $ 120.3
Robert Rubin	Independent Director	15yrs	US$80.00k	0.00083% $ 73.4
Dorothy Mary Keefe	Member of Oral Mucositis Medical Advisory Board	no data	pas de données	pas de données
Jeffrey Hyams	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	pas de données	pas de données
James Markowitz	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	pas de données	pas de données
Joel Rosh	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	pas de données	pas de données
Alain Rook	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	pas de données	pas de données
Mark Schubert	Member of Oral Mucositis Medical Advisory Board	no data	pas de données	pas de données
Youn Kim	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	pas de données	pas de données
Gary Wood	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	pas de données	pas de données

15.3yrs

Durée moyenne de l'emploi

69.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration 0A6I sont chevronnés et expérimentés (durée moyenne d'administration 15.1 ans).

Soligenix Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

Insufficient new directors

Insufficient new directors

Insufficient new directors

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Recent updates

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Second quarter 2024 earnings released: US$1.31 loss per share (vs US$3.56 loss in 2Q 2023)

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

First quarter 2024 earnings released: US$0.18 loss per share (vs US$0.36 loss in 1Q 2023)

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Full year 2023 earnings released: US$0.79 loss per share (vs US$4.81 loss in FY 2022)

No longer forecast to breakeven

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

Insufficient new directors

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Third quarter 2023 earnings released: US$0.16 loss per share (vs US$1.15 loss in 3Q 2022)

Insufficient new directors

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Insufficient new directors

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

First quarter 2023 earnings released: US$0.36 loss per share (vs US$1.52 loss in 1Q 2022)

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

Insufficient new directors

No longer forecast to breakeven

No longer forecast to breakeven

Insufficient new directors

Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen